| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-159 |
Sentence |
denotes |
[Late appearance of Philadelphia chromosome with the p190 BCR/ABL chimeric transcript in acute myelogenous leukemia progressing from myelodysplastic syndrome]. |
| T1 |
0-159 |
Sentence |
denotes |
[Late appearance of Philadelphia chromosome with the p190 BCR/ABL chimeric transcript in acute myelogenous leukemia progressing from myelodysplastic syndrome]. |
| TextSentencer_T2 |
160-382 |
Sentence |
denotes |
We report a late appearance of the Philadelphia chromosome (Ph) with the p190 BCR/ABL chimeric transcript in a 69-year-old patient with acute myelogenous leukemia (AML) that had evolved from myelodysplastic syndrome (MDS). |
| T2 |
160-382 |
Sentence |
denotes |
We report a late appearance of the Philadelphia chromosome (Ph) with the p190 BCR/ABL chimeric transcript in a 69-year-old patient with acute myelogenous leukemia (AML) that had evolved from myelodysplastic syndrome (MDS). |
| TextSentencer_T3 |
383-526 |
Sentence |
denotes |
In July 1997, the patient was found to have pancytopenia caused by refractory anemia with excess of blasts, which evolved into AML in 4 months. |
| T3 |
383-526 |
Sentence |
denotes |
In July 1997, the patient was found to have pancytopenia caused by refractory anemia with excess of blasts, which evolved into AML in 4 months. |
| TextSentencer_T4 |
527-620 |
Sentence |
denotes |
The leukemic cells were positive for CD13, CD14, CD33, and HLA-DR and had a normal karyotype. |
| T4 |
527-620 |
Sentence |
denotes |
The leukemic cells were positive for CD13, CD14, CD33, and HLA-DR and had a normal karyotype. |
| TextSentencer_T5 |
621-694 |
Sentence |
denotes |
The patient achieved a complete remission after combination chemotherapy. |
| T5 |
621-694 |
Sentence |
denotes |
The patient achieved a complete remission after combination chemotherapy. |
| TextSentencer_T6 |
695-863 |
Sentence |
denotes |
However, his leukemia relapsed in November 1999, with the appearance of leukemic cells positive for CD7, CD13, CD34, and HLA-DR with a 46, XY, add (18) (p11) karyotype. |
| T6 |
695-863 |
Sentence |
denotes |
However, his leukemia relapsed in November 1999, with the appearance of leukemic cells positive for CD7, CD13, CD34, and HLA-DR with a 46, XY, add (18) (p11) karyotype. |
| TextSentencer_T7 |
864-963 |
Sentence |
denotes |
The patient failed to achieve the second remission after several courses of intensive chemotherapy. |
| T7 |
864-963 |
Sentence |
denotes |
The patient failed to achieve the second remission after several courses of intensive chemotherapy. |
| TextSentencer_T8 |
964-1196 |
Sentence |
denotes |
When the number of blastic cells, showing the same surface phenotypes, in the peripheral blood increased drastically in April 2000, chromosomal analysis of leukemic cells revealed a 46, XY, t(9;22) (q34;q11), add(18)(p11) karyotype. |
| T8 |
964-1196 |
Sentence |
denotes |
When the number of blastic cells, showing the same surface phenotypes, in the peripheral blood increased drastically in April 2000, chromosomal analysis of leukemic cells revealed a 46, XY, t(9;22) (q34;q11), add(18)(p11) karyotype. |
| TextSentencer_T9 |
1197-1430 |
Sentence |
denotes |
The fusion of the BCR and ABL genes was confirmed by fluorescence in situ hybridization analysis, and the reverse transcription-polymerase chain reaction analysis further revealed the presence of the p190 BCR/ABL chimeric transcript. |
| T9 |
1197-1430 |
Sentence |
denotes |
The fusion of the BCR and ABL genes was confirmed by fluorescence in situ hybridization analysis, and the reverse transcription-polymerase chain reaction analysis further revealed the presence of the p190 BCR/ABL chimeric transcript. |
| TextSentencer_T10 |
1431-1570 |
Sentence |
denotes |
The appearance of the Ph chromosome in the course of MDS transforming to AML is very rare and may be correlated to the disease progression. |
| T10 |
1431-1570 |
Sentence |
denotes |
The appearance of the Ph chromosome in the course of MDS transforming to AML is very rare and may be correlated to the disease progression. |